FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to oncology and concerns a complex containing a combination of polyinosinic-polycytidylic acid (pIC) and polyethylenimine (PEI), and using it as an agent for treating cancer, particularly melanoma.
EFFECT: invention contains a pharmaceutical composition containing the complex applicable in treating melanoma, wherein the above complex induces autophagia in melanoma cells or in a cell line produced from the melanoma cells, and the above complex contains the combination of pIC and linear PEI in N/P ratio 1:5.
10 cl, 1 tbl, 13 ex, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT INDUCING CELL DEATH FOR CELLS HAVING BRAF GENE MUTATIONS, AGENT SUPPRESSING GROWTH OF SUCH CELLS, AND PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF DISEASES CAUSED BY GROWTH DEFECT OF SUCH CELLS | 2016 |
|
RU2760835C2 |
| APOPTOSIS-INDUCING MEANS | 2011 |
|
RU2639459C2 |
| NIDO-CARBORAN-CONTAINING FOLIC ACID BIS-AMIDES FOR BORON DELIVERY TO TUMOR CELLS | 2022 |
|
RU2794768C1 |
| APPLICATION OF MYXOMA VIRUS FOR THERAPEUTIC TREATMENT OF CANCER AND CHRONIC VIRUS INFECTION | 2004 |
|
RU2362584C2 |
| AGENT PREVENTING MAMMAL NORMAL CELL TRANSFORMATION IN MALIGNANT CELLS | 2010 |
|
RU2429839C1 |
| ANTI-IL1RAP ANTIBODIES AND THEIR USE FOR TREATING HUMAN | 2012 |
|
RU2597831C2 |
| QUINAZOLINE DERIVATIVES INDUCING FERROPTOSIS IN METASTATIC MELANOMA CELLS AND COLON CANCER | 2019 |
|
RU2722308C1 |
| METHODS FOR CANCER TREATMENT USING AUTOPHAGY INHIBITOR BASED ON THIOXANTHONE | 2011 |
|
RU2627588C2 |
| USE OF GENETICALLY MODIFIED PATHOGENIC MEASLES VIRUS WITH IMPROVED APOPTOTIC PROPERTIES (MV-DELTAC VIRUS) IN CANCER THERAPY | 2014 |
|
RU2700083C2 |
| MAGNETIC METAL OXIDE COATED POLYMER NANOPARTICLES AND USE THEREOF | 2008 |
|
RU2472530C2 |
